{
    "clinical_study": {
        "@rank": "163399", 
        "brief_summary": {
            "textblock": "The objective is to determine the safety and efficacy of dexosome immunotherapy in patients\n      with Stage IV malignant melanoma"
        }, 
        "brief_title": "Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma", 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic\n             disease.\n\n          -  All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung\n             metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA\n             type A1, A2, or B35.\n\n          -  Patients must have adequate organ function and an estimated life expectancy of at\n             least 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "July 30, 2002", 
        "id_info": {
            "nct_id": "NCT00042497", 
            "org_study_id": "AN2002-04"
        }, 
        "intervention": {
            "intervention_name": "autologous dexosomes loaded with tumor-specific peptides", 
            "intervention_type": "Biological"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "official_title": "A Phase II, Multicenter, Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma", 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042497"
        }, 
        "source": "Anosys", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Anosys", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2002"
    }, 
    "geocoordinates": {}
}